Its integrated in silico–in vivo profile suggests that it may complement or potentially enhance the benefits of existing SGLT2 inhibitors, offering broader metabolic and organ protection in T2DM [9,10,11,12,18,19,20,21,22,25,26,27,28,29,30,31]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.